Author

H. Hammond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:human· 1 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Dillen· 2 shared G. Smith· 2 shared M. Frieman· 2 shared N. Patel· 2 shared R. Johnson· 2 shared S. Weston· 2 shared A. D. Portnoff· 1 shared B. Ekechukwu· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. Dillen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Diet Induced Obesity and Diabetes Enhance Mortality and Reduces Vaccine Efficacy for SARS-CoV-2

R. Johnson, J. Ardunay, H. Hammond, J. Logue, L. Jackson, L. Baracco, M. McGrath, C. Dillen, N. Patel, G. Smith, M. Frieman

This study shows that obesity and diabetes increase SARS-CoV-2 mortality and reduce vaccine efficacy in mice, with neutrophil depletion improving outcomes.

bioRxiv · Oct 15, 2022Microbiology

Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

D. Schultz, R. Johnson, K. Ayyanathan, J. Miller, K. Whig, B. Kamalia, M. Dittmar, S. Weston, H. Hammond, C. Dillen, L. Castellana, J. S. Lee, M. Li, E. M. Lee, S. Constant, , S. Cherry

The paper screens 18,000 drugs for antiviral activity against SARS-CoV-2, identifies synergistic combinations of pyrimidine biosynthesis inhibitors and nucleoside analogs, and validates their efficacy in vitro and in vivo.

bioRxiv · Jun 24, 2021 · PreprintMicrobiology

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, J. Lague, A. D. Portnoff, J. Norton, M. Guebre-Xabier, B. Zhou, K. Jacobson, S. Maciejewski, R. Khatoon, M. Wisniewska, , G. Smith

This study evaluates the immunogenicity and protective efficacy of the NVX-CoV2373 SARS-CoV-2 vaccine in baboons and mice, showing strong immune responses and protection without enhanced disease.

bioRxiv · Jun 29, 2020Microbiology